Market Movers rounds up the best investor and analyst reactions to Biogen. Experts discuss the biotech company after the Food and Drug Administration approved its Alzheimer’s disease treatment Leqembi, paving the way for broader health insurance coverage. The drug slowed cognitive decline in trials but carries risks of brain swelling and bleeding, and costs $26,500 a year. Biogen is partnering with Japanese pharmaceutical company Eisai to manufacture Leqembi. Despite the approval, shares of Biogen were down more than 3% at Friday’s close and are down nearly 10% over the past month.
